This was Citius second try for FDA approval, after the regulator rejected Lymphir in July 2023, outlining the need for enhanced product resting requirements. In its resubmitted data package, the company included findings from the from the Phase III Study 302 trial, where treatment with the drug led to an objective response rate of 36.2%, with 8.7% reaching complete response
Our data differ from the whole animal reports in that a) only a single cell type is being analyzed under controlled conditions, b) pneumocytes, not bronchial or tracheal cells, are the focus and c) ozone exposure is within environmentally relevant levels
Many senolytic drugs are already approved for human use and many cells expressing senescence have been identified in other types of chronic kidney disease, however these studies did not include patients with lupus
This is because of their anti melanogenic effects, which prevent skin pigmentation and lead to skin lightening
Nanotechnology approaches for inhalation treatment of lung diseases
